Bernard Marini, PharmD, BCOP

Clinical Pharmacist Specialist - Hematology
Residency Program Director- PGY2 Oncology
Clinical Associate Professor of Pharmacy
Rotation(s) Offered: Inpatient Hematology


I primarily cover patients with acute leukemias, aggressive lymphomas, and other challenging hematologic malignancies. I also work with our pediatric brain tumor group on precision medicine initiatives and the investigation of blood brain barrier penetration of targeted therapies. 

Pharmacy School Attended: University of Michigan (2012)

Other Training: 

  • PGY1 Pharmacy: University of Michigan (2013)
  • PGY2 Oncology: University of Michigan (2014)

Areas of Interest

Hematology, Immunocompromised infectious diseases, Brain tumors & Precision medicine

Honors & Awards

PGY2 Oncology Residency Preceptor of the Year,2019

Published Articles or Reviews

  • Reid JH, Durant KM, Chen SL, Perissinotti AJ, King R, Khoriaty R, Marini BL. Role of caplacizumabin the treatment of acquired thrombotic thrombocytopenic purpura [published online ahead of print, 2020 Jun 30]. J Oncol Pharm Pract. 2020;1078155220934862.
  • Miklja Z, ... Marini BL, Koschmann C. Everolimusimproves the efficacy of dasatinib in PDGFRα-driven glioma [published online ahead of print, 2020 Jun 30]. J Clin Invest. 2020;133310. doi:10.1172/JCI133310
  • Reid JH, Marini BL, Nachar VR, Brown AM, Devata S, Perissinotti AJ. Contemporary treatment optionsfor a classical disease: Advanced Hodgkin lymphoma. Crit Rev Oncol Hematol. 2020;148:102897. doi:10.1016/j.critrevonc.2020.102897
  • Wierzbicki K, Ravi K, Franson A, Bruzek A, Cantor E, Harris M, Homan MJ, Marini BL, Kawakibi AR, Ravindran R, Teodoro R, Yadav VN, Koschmann C. Targeting and Therapeutic Monitoring of H3K27M-Mutant Glioma [published correction appears in Curr Oncol Rep. 2020 Apr 16;22(5):47]. Curr Oncol Rep. 2020;22(2):19. Published 2020 Feb 6. doi:10.1007/s11912-020-0877-0
  • Weis TM, Marini BL, Nachar VR, Brown AM, Phillips TJ, Brown J, Wilcox RA, Kaminski MS, Devata S, Perissinotti AJ. Impact of a vincristine dose cap on the incidence of neuropathies with DA-EPOCH-R for the treatment of aggressive lymphomas. Leuk Lymphoma. 2019 Dec 26;1-7. doi: 10.1080/10428194.2019.1703969. 
  • Hoylman E, Brown A, Perissinotti AJ, Marini BL, Pianko M, Ye JC, Campagnaro E, Nachar VR. Optimal sequence of daratumumab and elotuzumab in relapsed and refractory multiple myeloma. Leuk Lymphoma. 2019 Nov 18;1-8. doi: 10.1080/10428194.2019.1688324. [Epub ahead of print]. PMID: 31739729.
  • Reid JH, Perissinotti AJ, Benitez L, Bixby DL, Burke P, Pettit K, Marini BL. Impact of prophylactic intrathecal chemotherapy on CNS relapse rates in AML patients presenting with hyperleukocytosis. Leuk Lymphoma. 2019 Nov 18;1-7. doi: 10.1080/10428194.2019.1691199. [Epub ahead of print]. PMID: 31739707.
  • Alsawah F, Benitez L, Choi S, Marini B, Perissinotti A, Skyles A, Burke P, Pettit K, Crouch A, Fox H, Bixby D. Intrathecal alemtuzumab: a potential treatment of refractory leptomeningeal T-cell prolymphocytic leukemia. Blood Adv. 2019 Nov 12;3(21):3333-3336. doi: 10.1182/bloodadvances.2019000289. PMID: 31698446; PMCID: PMC6855106.
  • Merz LE, Perissinotti AJ, Marini BL, Burke PW, Crouch A, Erba HP, Bixby D. Lenalidomide Plus Hypomethylating Agent as a Treatment Option in Acute Myeloid Leukemia With Recurrent Genetic Abnormalities-AML With inv(3)(q21.3q26.2) or t(3;3)(q21.3;q26.2); GATA2, MECOM. Clin Lymphoma Myeloma Leuk. 2019 Sep 28. pii: S2152-2650(19)32002-6. doi: 10.1016/j.clml.2019.09.615. [Epub ahead of print] PubMed PMID: 31711889
  • Weis TM, Perissinotti AJ, Nachar VR, Brown A, Phillips TP, Marini BL. Dosing vincristine in DA-EPOCH-R: to cap or not to cap? J Clin Oncol. 2019. J Clin Oncol. 2019 Sep 18:JCO1901259. doi: 10.1200/JCO.19.01259. [Epub ahead of print] PubMed PMID: 31532723.
  • Marini BL, Perissinotti AJ, Bixby DL, Burke PW, Pettit KM, Benitez LL. Mini-HCVD plus inotuzumab plus or minus blinatumomab: Hype or hope? 10 July 2019.
  • Weis TM, Marini BL, Bixby DL, Perissinotti AJ. Clinical considerations for the use of FLT3 inhibitors in acute myeloid leukemia. Crit Rev Oncol Hematol. 2019 Jun 28;141:125-138. doi: 10.1016/j.critrevonc.2019.06.011. [Epub ahead of print]
  • Patel HP, Perissinotti AJ, Patel TS, Bixby DL, Marshall VD, Marini BL. Incidence and Risk Factors for Breakthrough Invasive Mold Infections in Acute Myeloid Leukemia Patients Receiving Remission Induction Chemotherapy. Open Forum Infect Dis. 2019 Apr 12;6(5):ofz176. doi: 10.1093/ofid/ofz176.
  • Marini BL, Brown J, Benitez L, Walling E, Hutchinson RJ, Mody R, Jasty Rao R, Slagle L, Bishop L, Pettit K, Bixby DL, Burke PW, Perissinotti AJ. A single-center multidisciplinary approach to managing the global Erwinia asparaginase shortage. Leuk Lymphoma. 2019 May 17:1-15. doi: 10.1080/10428194.2019.1608530.
  • Reid JH, Marini BL, Nachar VR, Devata S, Perissinotti AJ. PET-guided, BEACOPP(escalated) therapy inadvanced Hodgkin lymphoma. Lancet Oncol. 2019 Apr;20(4):e188. doi: 10.1016/S1470-2045(19)30081-6.
  • Chappell G, Geer M, Gatza E, Braun T, Churay T, Brisson J, Bixby D, Marini B, Perissinotti A, Frame D, Parkin B, Reddy P, Magenau J, Choi SW. Maintenance sorafenib in FLT3-ITD AML following allogeneic HCT favorably impacts relapse and overall survival. Bone Marrow Transplant. 2019 Feb 26.
  • Miklja Z, Pasternak A, Stallard S, Nicolaides T, Kline-Nunnally C, Cole B, Beroukhim R, Bandopadhayay P, Chi S, Ramkissoon SH, Mullan B, Bruzek AK, Gauthier A, Garcia T, Atchison C, Marini B, Fouladi M, Parsons DW, Leary S, Mueller S, Ligon KL, Koschmann C. Molecular profiling and targeted therapy in pediatric gliomas: review and consensus recommendations. Neuro Oncol. 2019 Feb 26
  • Robinson AC, Marini BL, Pettit KM, Perissinotti AJ. Successful use of blinatumomab in a patient with acute lymphoblastic leukemia andsevere hepatic dysfunction. J Oncol Pharm Pract. 2019 
  • Cheung E, Perissinotti AJ, Bixby DL, Burke PW, Pettit KM, Benitez LL, Brown J, Scappaticci GB, Marini BL. The leukemia strikes back: a review of pathogenesis and treatment of secondary AML. Ann Hematol. 2019 Jan 21.
  • Perissinotti AJ, Marini BL. Managing liver dysfunction in haematology patients: Switch antifungals, or use the tincture of time? Mycoses. 2018 Nov 26.
  • Vulaj V, Perissinotti AJ, Uebel JR, Nachar VR, Scappaticci GB, Crouch A, Bixby DL, Burke PW, Maillard I, Talpaz M, Marini BL. The FOSSIL Study: FLAG or standard 7+3 induction therapy in secondary acute myeloid leukemia. Leuk Res. 2018. 
  • Koschmann C, Wu Y, Kumar-Sinha C, Lonigro R, Vats P, Kasaian K, Cieslik M, Cao X, Frank K, Prensner J, Zurieck A, Everett J, Anderson B, Marini B, Camelo-Piragua S, Venneti S, McKeever P, McFadden K, Lieberman A, Leonard M, Maher C, Garton H, Muraszko K, Robertson P, Robinson D, Chinnaiyan A, Mody R. Clinically integrated sequencing significantly alters therapy in children and young adults with high-risk glial braintumors. JCO Precision Oncology 2018 :2, 1-34
  • Ettleson M, Bongers KS, Vitale K, Perissinotti AJ, Phillips T, Marini BL. Successful use of cytarabine and bendamustine in a patient with mantle cell lymphoma and acute renal failure using intermittent hemodialysis: A case report. J Oncol Pharm Pract. 2018 Jan 1. 
  • Scappaticci GB, Marini BL, Nachar VR, Uebel JR, Vulaj V, Crouch A, Bixby DL, Talpaz M, PerissinottiAJ. Outcomes of previously untreated elderly patients with AML: a propensity score-matched comparison of clofarabine vs. FLAG. Ann Hematol. 2018 Apr;97(4):573-584.
  • Linzey JR, Marini BL, Pasternak A, Smith C, Miklja Z, Zhao L, Kumar-Sinha C, Paul A, Harris N, Robertson PL, Hoffman LM, Chinnaiyan A, Mody R, Koschmann C. Development of the CNS TAP tool for the selection of precision medicine therapies in neuro-oncology. J Neurooncol. 2017 Dec 12.
  • Nachar VR, Perissinotti AJ, Scappaticci GB, Bixby DL, Marini BL. Predictors for requiring re-induction chemotherapy in acute myeloid leukemia patients with residual disease on day 14 bone marrow assessment. Leuk Res. 2017 Dec;63:56-61. 
  • Neumann DR, Marini BL, Phillips TJ, Wilcox RA, Mayer TL, Brown A, Perissinotti AJ. Pegasparaginase silent inactivation during therapy for NK/T cell lymphoma. Leuk Lymphoma. 2017Nov 6:1-10.
  • Marini BL, Benitez LL, Zureick AH, Salloum R, Gauthier AC, Brown J, Wu YM, Robinson DR, Kumar C, Lonigro R, Vats P, Cao X, Kasaian K, Anderson B, Mullan B, Chandler B, Linzey JR, Camelo-Piragua SI, Venneti S, McKeever PE, McFadden KA, Lieberman AP, Brown N, Shao L, Leonard MAS, Junck L, McKean E, Maher CO, Garton HJL, Muraszko KM, Hervey-Jumper S, Mulcahy-Levy JM, Green A, Hoffman LM, Dorris K, Vitanza NA, Wang J, Schwartz J, Lulla R, Smiley NP, Bornhorst M, Haas-Kogan DA, Robertson PL, Chinnaiyan AM, Mody R, Koschmann C. Blood-brain barrier-adapted precision medicine therapy for pediatric brain tumors. Transl Res. 2017 Oct;188:27. 
  • Salzer W, Bostrom B, Messinger Y, Perissinotti AJ, Marini B. Asparaginase activity levels and monitoring in patients with acute lymphoblastic leukemia. Leuk Lymphoma. 2017 Oct 18:1-10. 
  • Perissinotti AJ and Marini BL. Real-life challenges to the use of antifungal agents in hematology patients. Curr Fungal Infect Rep. 2017 Oct;11: 229-241. 
  • Tang LA, Marini BL, Benitez L, Nagel JL, Miceli M, Berglund C, Perissinotti AJ. Risk factors for subtherapeutic levels of posaconazole tablet. J Antimicrob Chemother. 2017 Oct 1;72(10):2902-2905.
  • Marini BL, Perissinotti AJ, Bixby DL, Brown J, Burke PW. Catalyzing improvements in ALL therapy with asparaginase. Blood Rev. 2017 Sep;31(5):328-338. 
  • Rausch CR, Marini BL, Benitez LL, Elias A, Burke PW, Bixby D, Perissinotti AJ. PEGging down risk factors for peg-asparaginase hepatotoxicity in patients with acute lymphoblastic leukemia. Leuk Lymphoma. 2017 Jul 18:1-8. 
  • Linzey JR, Marini BL, McFadden K, Lorenzana A, Mody R, Robertson PL and Koschmann C. Identification and targeting of a novel FGFR fusion in a pediatric thalamic “central oligodendroglioma.” npj Precision Oncology (2017) 1:29;
  • Herc ES, Kauffman CA, Marini BL, Perissinotti AJ, Miceli MH. Daptomycin nonsusceptible vancomycin resistant Enterococcus bloodstream infections in patients with hematological malignancies: risk factors andoutcomes. Leuk Lymphoma. 2017 Apr 12:1-7. 
  • Scappaticci GB, Perissinotti AJ, Nagel JL, Bixby DL, Marini BL. Risk factors and impact of Clostridium difficile recurrence on haematology patients. J Antimicrob Chemother. 2017 Feb 10.
  • Boyd AM, Perissinotti AJ, Nagel JL, Frame DG, Marini BL. Risk factors for cefepime nonsusceptible Gram-negative infections in allogeneic hematopoietic cell transplant recipients. J Oncol Pharm Pract. 2017 Jan 1:1078155217731507
  • Shaikh SA, Marini BL, Hough SM, Perissinotti AJ. Rational use of rasburicase for the treatment and management of tumor lysis syndrome. J Oncol Pharm Pract. 2017 Jan 1:1078155216687152. [Epub ahead of print]
  • DasGupta RK, Marini BL, Rudoni J, Perissinotti AJ. A review of CD19-targeted immunotherapies for relapsed or refractory acute lymphoblastic leukemia. J Oncol Pharm Pract. 2017 Jan 1:1078155217713363. [Epub ahead of print]
  • Barker JA, Marini BL, Bixby D, Perissinotti AJ. Successful useof high-dose cytarabine in a patient with acute myeloid leukemia and severe hepatic dysfunction. J Oncol Pharm Pract. 2016 Dec;22(6):811-815.
  • Marini BL, Sun Y, Burke PW, Perissinotti AJ. Successful reintroduction of blinatumomab in a patient with relapsed/refractory acute lymphoblastic leukemia following grade 4 cytokine release syndrome. J Oncol Pharm Pract. 2016 Oct 31. [Epub ahead of print]
  • Ganti BR, Marini BL, Nagel J, Bixby D, Perissinotti AJ. Impact of Antibacterial Prophylaxis during Reinduction Chemotherapy for Relapse/Refractory Acute Myeloid Leukemia. Support Care Cancer. 2016 Oct 14. [Epub ahead of print]
  • Koschmann C, Zamler D, MacKay A, Robinson D, Wu YM, Doherty R, Marini B, Tran D, Garton H, Muraszko K, Robertson P, Leonard M, Zhao L, Bixby D,Peterson L, Camelo-Piragua S, Jones C, Mody R, Lowenstein PR, Castro MG. Characterizing and targeting PDGFRA alterations in pediatric high-grade glioma. Oncotarget. 2016 Aug 25. [Epub ahead of print]
  • Marini BL, Samanas L, Perissinotti AJ. Expanding the armamentarium for chronic lymphocytic leukemia: A review of novel agents in the management of chronic lymphocytic leukemia. J Oncol Pharm Pract. 2016 Jun 29. [Epub ahead of print]
  • Marini BL, Markstrom D, Frame D. Risk of graft-versus-host disease with rituximab-containing conditioning regimens in allogeneic hematopoietic stem cell transplant. J Oncol Pharm Pract. 2016 Mar 11. [Epub ahead of print]
  • Marini BL, Wechter AR, Burke PW, Bixby D, Perissinotti AJ. Minimizing waste during preparation of blinatumomab infusions. Am J Health Syst Pharm. 2016 Jan 15;73(2):19-20.
  • Benitez L, Perissinotti AJ, Santarossa M, Marini BL. Pharmacokinetic and clinical considerations for monitoring asparaginase activity levels during pegaspargase therapy. Pediatr Blood Cancer. 2015 Jun;62(6):1115.
  • Marini BL, Hough SM, Gregg KS, Abu-Seir H, Nagel JL. Risk factors for piperacillin/tazobactam-resistant gram-negative infection in hematology/oncology patients with febrile neutropenia. Support Care Cancer. 2015 Aug;23(8):2287-95.